Exploring uncharted territory. Building on important collaborations. Persevering where others have failed. These are the principles that guide Genentech.
In 1976, Herb Boyer and Bob Swanson sat down over a couple of beers, scratched some notes on the back of an envelope and imagined a company that would change the course of medicine. At the forefront of revolutionary science, they discussed using recombinant DNA technology to produce new medical treatments. Today Genentech has grown to 11,000 employees, all focused on drug discovery efforts to develop safer and more effective therapies for life-threatening illnesses.
When the company needed a new facility, Genentech imagined a center unlike any other in the industry. They combined labs and the pilot plant, bridging the gap between research, testing, and manufacturing. By locating all of these diverse professionals in one building, Genentech significantly enhanced communication and collaboration among scientists and shortened the time needed to bring new products to market.
This innovation has not only won awards. It has made a dramatic impact on those who suffer from cancer, cystic fibrosis, asthma, macular degeneration, multiple sclerosis, rheumatoid arthritis, and lupus.